# Morepen Laboratories (NSE: MOREPENLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MOREPENLAB · Pivot · prices to 30 Sep 2026

Morepen Laboratories (NSE: MOREPENLAB) closed at ₹125.70 on 30 Sep 2026. With a market capitalisation of ₹6,888 Cr, it ranks 669th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 72.7× trailing earnings, against a return on equity of 7.6% in FY26. Over the past year the share price has risen 141.6%. Its 52-week range is ₹33.05 (30 Mar 2026) to ₹128.10 (30 Sep 2026); the last close is 1.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹570 Cr (+34.1% year on year) and net profit ₹56 Cr (+393.9%), on a consolidated basis. Promoters held 35.65% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹125.70 |
| Market cap | ₹6,888 Cr |
| P/E (trailing) | 72.7 |
| ROE | 7.6% (FY26) |
| ROCE | 7.6% (FY26) |
| Debt to equity | 0.16 |
| 52-week high | ₹128.10 (30 Sep 2026) |
| 52-week low | ₹33.05 (30 Mar 2026) |
| 1-year return | +141.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹570 Cr | +34.1% | ₹56 Cr | +393.9% | ₹1.03 |
| Q4 FY26 | ₹485 Cr | +4.1% | ₹16 Cr | −22.7% | ₹0.28 |
| Q3 FY26 | ₹484 Cr | +6.9% | ₹28 Cr | +3.0% | ₹0.50 |
| Q2 FY26 | ₹412 Cr | −6.0% | ₹41 Cr | +17.8% | ₹0.75 |
| Q1 FY26 | ₹425 Cr | −6.6% | ₹11 Cr | −68.5% | ₹0.20 |
| Q4 FY25 | ₹466 Cr | +10.1% | ₹20 Cr | −29.3% | ₹0.35 |
| Q3 FY25 | ₹453 Cr | +1.9% | ₹27 Cr | −16.6% | ₹0.49 |
| Q2 FY25 | ₹438 Cr | +3.8% | ₹35 Cr | +63.9% | ₹0.65 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,812 Cr | ₹118 Cr |
| FY24 | ₹1,690 Cr | ₹97 Cr |
| FY23 | ₹1,418 Cr | ₹39 Cr |
| FY22 | ₹1,547 Cr | ₹102 Cr |
| FY21 | ₹1,188 Cr | ₹97 Cr |
| FY20 | ₹853 Cr | ₹34 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 35.65%
- Foreign institutions: 1.46%
- Domestic institutions: 1.28%
- Non-institutions: 61.59%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Thyrocare Technologies](https://app.pivotnow.in/stock/THYROCARE) | ₹470.65 | ₹7,491 Cr | 46.2 | — |
| [Supriya Lifescience](https://app.pivotnow.in/stock/SUPRIYA) | ₹848.80 | ₹6,831 Cr | 32.7 | — |
| [Bliss GVS Pharma](https://app.pivotnow.in/stock/BLISSGVS) | ₹638.00 | ₹6,766 Cr | 53.1 | — |
| [Sanofi India](https://app.pivotnow.in/stock/SANOFI) | ₹2,845.00 | ₹6,552 Cr | 21.2 | — |
| [Entero Healthcare Solutions](https://app.pivotnow.in/stock/ENTERO) | ₹1,504.20 | ₹6,547 Cr | 57.1 | — |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |

## Questions and answers

### What is the share price of Morepen Laboratories today?

Morepen Laboratories (NSE: MOREPENLAB) last closed at ₹125.70 on 30 Sep 2026. Its 52-week high is ₹128.10 and its 52-week low is ₹33.05.

### What is the market cap of Morepen Laboratories?

Morepen Laboratories' market capitalisation is ₹6,888 Cr (₹6,888 Cr) at the 22 Oct 2026 close, ranking 669th among the NSE companies Pivot tracks.

### What is the P/E ratio of Morepen Laboratories?

Morepen Laboratories trades at a trailing P/E of 72.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.2.

### What is the ROE and ROCE of Morepen Laboratories?

Return on equity was 7.6% in FY26 and return on capital employed was 7.6% in FY26 (consolidated figures).

### Is Morepen Laboratories a debt-free company?

No. Morepen Laboratories' debt-to-equity ratio was 0.16 in FY26, with total debt of ₹134 Cr.

### What were Morepen Laboratories' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Morepen Laboratories reported revenue of ₹570 Cr, +34.1% year on year, and net profit of ₹56 Cr, +393.9% year on year.

### How has Morepen Laboratories stock performed over the last year?

Morepen Laboratories' share price has risen 141.6% over the past year, +111.3% over three months and +17.1% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Morepen Laboratories?

As of 30 Jun 2026: promoters 35.65%, foreign institutions 1.46%, domestic institutions 1.28%, non-institutions 61.59%.

### Who are Morepen Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Morepen Laboratories by market cap are Thyrocare Technologies, Supriya Lifescience, Bliss GVS Pharma, Sanofi India, Entero Healthcare Solutions and Kovai Medical Center & Hospital.

### Is Morepen Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Morepen Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MOREPENLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.